News & Events

Learn about what's new with CMC Biologics

Serendex Pharmaceuticals and CMC Biologics Enter Exclusive Agreement on Factor VIIa


Copenhagen, Denmark and Seattle, WA – January 30, 2015 – Serendex Pharmaceuticals A/S (XOSL: SENDEX) and CMC Biologics, Inc. have today signed an exclusive agreement on Factor VIIa. Through the agreement, Serendex Pharmaceuticals has secured access to a unique form of Factor VIIa and the agreement provides Serendex Pharmaceuticals with exclusive rights for the development and commercialization of Factor VIIa for pulmonary administration. The therapeutic focus will be on acute bleeding in the lungs (Diffuse Alveolar Hemorrhage) and if successful Serendex Pharmaceuticals might be able to offer breakthrough therapy in this indication.

Follow Us
Join us on LinkedIn Follow us on Twitter